Track CVKD and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Cadrenal Therapeutics, Inc. Common Stock
822 A1A North, Ponte Vedra, FL, United States, 32082
IPO
2023
Employees
5
Industry
Biotechnology
Sector
Healthcare
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q4 202513-13
0
Q3 20257-7
0
2-quarter cumulative
20 sells0 buys
Analyst Ratings
1 analysts covering
Buy100%recommend buy
Buy
1
Hold
0
Sell
0